REGENXBIO Inc. has announced a significant leadership change following the resignation of Kenneth T. Mills from its board of directors. Mills will officially leave the board on October 21, 2026, as he transitions to a new role as chief executive officer at another company. His departure is not associated with any disagreements regarding the company’s operations, policies, or practices.
In light of Mills' resignation, REGENXBIO has appointed George Migausky as the new Chairman of the Board. This change in leadership is part of the company’s ongoing efforts to adapt and strengthen its governance structure. Daniel Tassé, the former Lead Independent Director, will remain on the board but will step down from his lead position, as the new Chairman is an independent director.
Background
REGENXBIO Inc. is a biotechnology company that specializes in the development of gene therapies. The company operates under the SIC code 2836, which pertains to biological products, excluding diagnostic substances. REGENXBIO is publicly traded on the Nasdaq under the ticker symbol RGNX. The company has been active in filing various reports with the SEC, including recent filings that demonstrate its ongoing operations and corporate governance.
What the Filing Says
The recent SEC filing states, "On October 14, 2026, Kenneth T. Mills resigned from the board of directors... Mr. Mills’ decision was not related to any disagreement with the Company on any matter relating to its operations, policies, or practices." It further notes that George Migausky has been appointed as the new Chairman of the Board.
Impact
This leadership transition may affect various stakeholders, including investors, employees, and partners within the biotechnology sector. The appointment of Migausky as Chairman suggests a potential shift in strategic direction, which could influence REGENXBIO's future initiatives and collaborations.
What's Next
The filing does not specify what happens next regarding additional board appointments or strategic changes. However, the company is expected to continue its focus on advancing its gene therapy programs and maintaining strong governance practices.